Skip to content
10-Q

Quarterly Report

Prevail Therapeutics Inc.

0001564590-20-025274

← back to feed
Filed
May 14, 2020 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2020 · May 7, 2020 34.2M sh
Capex Q1 2020 · Mar 31, 2020 $287K
Capex Q1 2020 · Mar 31, 2019 $256K
Operating Cash Flow Q1 2020 · Mar 31, 2020 −$18.25M
Operating Cash Flow Q1 2020 · Mar 31, 2019 −$12.33M
Cash And Equivalents Q1 2020 · Mar 31, 2020 $149.58M
Cash And Equivalents Q1 2020 · Dec 31, 2019 $168.05M
Cash And Equivalents Q1 2020 · Sep 30, 2019 $149.58M
Cash And Equivalents Q1 2020 · Sep 30, 2018 $100.27M
Stockholders Equity Q1 2020 · Mar 31, 2020 $148.46M
Stockholders Equity Q1 2020 · Dec 31, 2019 $165.34M
Stockholders Equity Q1 2020 · Mar 31, 2019 −$27.75M
Stockholders Equity Q1 2020 · Dec 31, 2018 −$18.42M
Current Liabilities Q1 2020 · Mar 31, 2020 $10.79M
Current Liabilities Q1 2020 · Dec 31, 2019 $11.83M
Total Liabilities Q1 2020 · Mar 31, 2020 $20.34M
Total Liabilities Q1 2020 · Dec 31, 2019 $21.76M
Current Assets Q1 2020 · Mar 31, 2020 $154.49M
Current Assets Q1 2020 · Dec 31, 2019 $174.46M
Total Assets Q1 2020 · Mar 31, 2020 $168.8M
Total Assets Q1 2020 · Dec 31, 2019 $187.1M
Sga Expense Q1 2020 · Mar 31, 2020 $7.86M
Sga Expense Q1 2020 · Mar 31, 2019 $1.89M
Rd Expense Q1 2020 · Mar 31, 2020 $11.42M
Rd Expense Q1 2020 · Mar 31, 2019 $8.41M
Net Income Q1 2020 · Mar 31, 2020 −$18.58M
Net Income Q1 2020 · Mar 31, 2019 −$9.95M
Operating Income Q1 2020 · Mar 31, 2020 −$19.28M
Operating Income Q1 2020 · Mar 31, 2019 −$10.3M